Indian Stock Market News, Equity Market and Sensex Today in India | Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

Sensex Ends 274 Points Lower; Dr Reddy's Laboratories and Cipla Among Top Nifty Losers
Tue, 27 Jul Closing

Indian share markets witnessed volatile trading activity throughout the day today and ended lower.

Benchmark indices were caught in the global crossfire as a heavy selloff in Chinese tech giants soured sentiment in late noon deals today.

Add to it, the US markets seemed nervous ahead of the Federal Reserve's two-day monetary policy meeting that kicks off later in the day.

At the closing bell, the BSE Sensex stood lower by 274 points (down 0.5%).

Meanwhile, the NSE Nifty closed lower by 78 points (down 0.5%).

Hindalco Industries and SBI Life Insurance were among the top gainers today.

Dr Reddy's Laboratories and Cipla, on the other hand, were among the top losers today.

The SGX Nifty was trading at 15,732, down by 89 points, at the time of writing.

The BSE MidCap index ended down by 0.6%, while the BSE SmallCap index ended on a flat note today.

Sectoral indices ended on a negative note with stocks in the healthcare sector and power sector witnessing most of the selling pressure.

Metal stocks, on the other hand, witnessed buying interest.

--- Advertisement ---
[Alert] Sell These 3 Stocks Immediately

These 3 stocks are ticking time bombs in your portfolio.

It is very likely that you could be owning these 3 overvalued...

fundamentally weak... ready to crash stocks... in your portfolio today.

Because many stock brokers have painted rosy pictures of these stocks. But the reality is starkly different.

If the market crashes, then these stocks could wipe out your wealth.

You should get rid of these stocks as soon as possible.

We are going to reveal details of these 3 landmines at our upcoming special event at 5 pm on September 24.

You can click here to sign-up. It's free

Shares of Bajaj Finserv and Ajanta Pharma hit their respective 52-week highs today.

Asian stock markets ended on a negative note today.

The Hang Seng and the Shanghai Composite ended the day down by 4.2% and 2.5%, respectively.

The Nikkei ended up by 0.5% in today's session.

US stock futures are trading on a negative note today with the Dow Futures trading down by 153 points.

The rupee is trading at 74.46 against the US$.

Gold prices for the latest contract on MCX are trading up by 0.1% at Rs 47,500 per 10 grams.

Speaking of the stock markets, India's #1 trader, Vijay Bhambwani, shares why he is sticking to his energy trading blueprint, in his latest video for Fast Profits Daily.

Tune in here to find out more:

In news from the pharma sector, Alembic Pharma was among the top buzzing stocks today.

Shares of Alembic Pharmaceuticals dipped 11.5% to Rs 800 on the BSE in intra-day trade today after the company reported disappointing numbers for the quarter ended June 2021.

The company's consolidated profit after tax (PAT) declined 45.4% year on year (YoY) to Rs 1.6 bn on weak performance of US business.

The pharmaceutical company had posted a PAT of Rs 3 bn in the first quarter of the year 2021.

Earnings before interest, taxes, depreciation, and amortization (EBITDA) margins declined 1,258 basis points (bps) YoY to 17.8% due to higher other expenditure.

The company's revenues declined 1.1% YoY to Rs 13.3 bn with strong growth in domestic formulations being offset by a 38.1% YoY decline in US sales to Rs 3.7 bn.

Domestic formulations grew 57.2% YoY to Rs 4.81 bn.

REVEALED: 3 "Super Smallcaps" You Didn't Know About

The acute and specialty segments grew faster than the represented pharmaceutical market, the company said.

The total expenses incurred by the company for the quarter ended 30 June 2021, stood at Rs 11.5bn. It was Rs 9.8 bn for the year-ago period.

Pranav Amin, Managing Director of Alembic Pharmaceuticals, said,

  • The India business grew exceptionally well and outpaced the industry, we hope to see this momentum continuing due to the initiatives undertaken recently.

    The US business faced price erosion due to increased competition. However, our long-term view of the US market remains intact.

Meanwhile, Alembic Pharma's research and development (R&D) spend increased by 17% during the quarter to Rs 1.7 bn, as compared to the said quarter last year.

Alembic Pharma share price ended the day down by 11.4% on the BSE.

Speaking of stocks, here is an illustration of the four phases that a stock goes through during its life cycle. The cycle repeats itself after the stock goes through all these for stages.

This cycle defines everything in markets. If you can master this cycle, then nothing can stop you from making huge profits.

If you're interested to know how a stock's life cycle can offer you the opportunity to make money in every phase, you can read about it in one of the recent editions of Profit Hunter: One Cycle That Defines Everything in the Markets

--- Advertisement ---
INSIDER SECRET: An Astonishingly Easy Way to Pile Up Potentially 40-60% Gains in Just 1 Year

India's most well-connected trader with over 35 years of experience just confessed...

"This Lucrative Market Segment Could Leapfrog Over Nifty in The Next 12-16 Months"

... thanks to a massive and irreversible mega-trend fueling its growth!

In fact, he and his partner have already identified 2 spectacular stocks from this segment... which are ready to rake in potentially 40-60% gains in just 1 year... and make you big, fat profits!

The best part of them all...

Their Details Are Packed in This Special Report (Discover How to Claim it for Free)

Moving on to news from the IPO space...

Glenmark Life Sciences IPO Subscribed 2.21 Times on Day 1

The initial public offering (IPO) of Glenmark Life Sciences has been subscribed 2.21 times on 27 July, the first day of bidding.

The offer has received bids for 33.1 m equity shares against the IPO size of 15 m equity shares, the subscription data available on exchanges showed.

The IPO size has been reduced to 15 m equity shares after the company garnered Rs 4.5 bn from anchor investors on 26 July, a day before the opening of the issue.

The reserved portion of retail investors has already been subscribed 4.13 times and that of non-institutional investors 60%.

Qualified institutional buyers have put in bids for 7,460 equity shares against their reserved portion of 4.2 m equity shares.

The subsidiary of Glenmark Pharma plans to raise Rs 15.1 bn through the public issue which comprises a fresh issue of Rs 10.6 bn, and an offer for sale of 6.3 m equity shares by promoter.

The price band for the offer, which will close on 29 July, has been fixed at Rs 695-720 per equity share.

How the IPO sails through remains to be seen. Meanwhile, stay tuned for more updates from this space.

To know what's moving the Indian stock markets today, check out the most recent share market updates here.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

Read the latest Market Commentary

What else is happening in the markets today? Dig in...

Equitymaster requests your view! Post a comment on "Sensex Ends 274 Points Lower; Dr Reddy's Laboratories and Cipla Among Top Nifty Losers". Click here!


Stock Market Updates

JINDAL STAINLESS (HISAR) at All Time High; BSE METAL Index Down 0.7% (Today's Market)

Sep 16, 2021 02:07 PM

JINDAL STAINLESS (HISAR) share price has hit an all time high at Rs 309 (up 2.6%). The BSE METAL Index is down by 0.7%. Among the top gainers in the BSE METAL Index today are JINDAL STAINLESS (HISAR) (up 2.6%) and VEDANTA (up 1.1%). The top losers include HINDUSTAN ZINC (down 0.1%) and COAL INDIA (down 0.7%).

COFORGE at All Time High; BSE IT Index Down 1.0% (Today's Market)

Sep 16, 2021 01:49 PM

COFORGE share price has hit an all time high at Rs 5,519 (up 1.3%). The BSE IT Index is down by 1.0%. Among the top gainers in the BSE IT Index today are COFORGE (up 1.3%) and TATA ELXSI (up 0.8%). The top losers include HEXAWARE TECHNOLOGIES and L&T INFOTECH (down 0.1%).

TCS at All Time High; BSE IT Index Down 0.9% (Today's Market)

Sep 16, 2021 01:47 PM

TCS share price has hit an all time high at Rs 3,982 (down 1.3%). The BSE IT Index is down by 0.9%. Among the top gainers in the BSE IT Index today are TCS (down 1.2%) and COFORGE (up 1.2%). The top losers include HEXAWARE TECHNOLOGIES and L&T INFOTECH (down 0.1%).

Sensex Trades Marginally Higher, Dow Futures Trade Flat (Today's Market)

Sep 16, 2021 12:30 pm

BSE Sensex is trading up by 263 points, while the NSE Nifty is up by 74 points.

Sensex Opens Marginally Higher; IndusInd Bank & ITC Top Gainers (Today's Market)

Sep 16, 2021 09:30 am

Indian share markets open in green. The BSE Sensex opened up by 128 points, while the Nifty is trading higher by 44 points.

JINDAL STAINLESS Share Price Up by 6%; BSE METAL Index Up 0.7% (Today's Market)

Sep 16, 2021 09:33 AM

JINDAL STAINLESS share price is trading up by 6% and its current market price is Rs 173. The BSE METAL is up by 0.7%. The top gainers in the BSE METAL Index is JINDAL STAINLESS (up 5.6%). The top losers are HINDALCO (down 0.2%) and HINDUSTAN ZINC (down 0.3%).

View More Indian Share Market News

Most Popular

5 Small-cap Stocks with Zero Debt(Views On News)

Sep 3, 2021

In this article, you will get a list of 5 debt free small-cap companies that are worth tracking.

Sansera Engineering IPO: Key Points to Consider(Views On News)

Sep 8, 2021

This IPO is a pure OFS and the company is looking to raise Rs 12.8 bn at the upper price band of Rs 744.

5 Stocks that Turned Rs 1 Lakh into Rs 1 Crore(Views On News)

Sep 7, 2021

Patience is one of the biggest virtues you need to have if you want to become a crorepati in the stock market.

Put the Odds in Your Favour to Find Smallcap Multibaggers(Profit Hunter)

Sep 3, 2021

A handy checklist to find multibagger smallcaps.

The Top Stocks to Sell in this Bull Market(Profit Hunter)

Sep 8, 2021

When I saw the list of so-called 'value stocks' published by a leading brokerage, my worst fears came true.


Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2021
Get our special report Multibagger Stocks Guide (2021 Edition) Now!
We will never sell or rent your email id.
Please read our Terms


Sep 16, 2021 (Close)